Nov 05, 2025
Philips and MedAdvisor Partner to Increase Awareness of Sleep Health Through Pharmacies
Sydney, Australia – November 2025: Philips Sleep and Respiratory Care has announced a new partnership with MedAdvisor, Australia’s leading digital medication management and pharmacy engagement platform, in a move designed to transform how patients access sleep health support. Through MedAdvisor’s pharmacy- and patient-facing platforms, this partnership is designed to help identify patients that may be at risk of Obstructive Sleep Apnoea (OSA) based on medications dispensed, considering those with sleep apnoea include:
The partnership demonstrates a growing trend in healthcare delivery, whereby pharmacies are increasingly becoming focal points for early intervention. With 80% of people who suffer from OSA being undiagnosed [5], this partnership means patients who are prescribed medication for co-morbid illnesses, such as GLP-1 receptor agonists to manage diabetes or weight loss, can be encouraged through in-app educational messaging or in-pharmacy prompts to complete a sleep apnoea screening quiz. As the partnership rolls out to assist Philip’s partner stores nationally, these interactions may lead to the early detection of OSA.
Philips' Pharmacy Sleep Services program is offered in hundreds of pharmacies around Australia. With the integration of MedAdvisor’s technology, pharmacists will now be empowered to proactively work with patients who may not be aware of their risk and share a sleep apnoea screening quiz. By embedding Philips’ sleep health education and screening tools into MedAdvisor’s systems, pharmacists will be better equipped to start meaningful conversations about sleep, set up patients for home sleep testing, and help them navigate therapy options.
Wayne Marinoff, Chief Executive Officer of MedAdvisor, said the partnership represents a powerful opportunity to drive earlier identification and management of sleep disorders in the community. “We’re proud to be partnering with Philips to deliver this important Sleep Apnoea Patient Care Program through community pharmacies across Australia. With the extensive reach and integration of the MedAdvisor platform, we’re uniquely positioned to help pharmacies identify and support eligible patients. As one of the most accessible touchpoints in healthcare, pharmacies play an increasingly important role in the ongoing management of patient care. Working with a global leader like Philips, a specialist in sleep and respiratory health, ensures this program is well positioned to deliver real impact through improved patient health outcomes.”
Shehaan Fernando, Philips Sleep and Respiratory Care Leader for APAC, said this partnership addresses one of the most significant barriers in the treatment of OSA – awareness. “This collaboration with MedAdvisor allows us to identify more consumers requiring critical therapy with the convenience of meeting patients where they are, in their local pharmacy,” he said. “By using technology to flag potential sleep issues and connect people with diagnostic pathways, we’re giving patients a smoother journey toward better sleep and overall wellbeing.”
Sleep disorders have strong implications for cardiovascular health, mental health, and daily functioning. By integrating sleep health education into pharmacy interactions, Philips and MedAdvisor are turning routine medication management into an opportunity to increase awareness and improve sleep health.
This partnership is an example of how digital interaction and pharmacy knowledge can join forces to make more accessible, proactive care possible at scale. By bringing Philips' experience in sleep health together with the objective of providing better care for more people, with MedAdvisor's extensive digital presence, the two firms are creating a more integrated healthcare experience, one in which patients, and their wellbeing, are placed squarely at the centre.
References [1] Marin, J.M., Carrizo, S.J., Vicente, E. & Navarro, J. (2005) ‘Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study’, The Lancet, 365(9464), pp. 1046–1053. [2] Buchner, N.J., Sanner, B.M., Borgel, J. & Randerath, W.J. (2007) ‘Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk’, American Journal of Respiratory and Critical Care Medicine, 176(12), pp. 1274–1280. [3] O’Keefe, T. & Patterson, E. (2004) ‘Evidence Supporting Routine Polysomnography Before Bariatric Surgery’, Obesity Surgery, 14, pp. 23–26. [4] Resnick, H.E., Redline, S., Shahar, E. (2003) ‘Diabetes and sleep disturbances: findings from the Sleep Heart Health Study’, Diabetes Care, 26, pp. 702–709. [5] Benjafield, A.V., Ayas, N.T., Eastwood, P.R., et al. (2019) ‘Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis’, Lancet Respiratory Medicine, 7(8), pp. 687–698.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
